| 143.4 -4.38 (-2.96%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 179.41 | 1-year : | 187.82 |
| Resists | First : | 153.6 | Second : | 160.8 |
| Pivot price | 147.08 |
|||
| Supports | First : | 141.94 | Second : | 118.1 |
| MAs | MA(5) : | 145.92 |
MA(20) : | 148.91 |
| MA(100) : | 124.82  |
MA(250) : | 101.27 |
|
| MACD | MACD : | 0.5 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 28.1 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 160.8 | Low : | 58.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PTGX ] has closed above bottom band by 9.1%. Bollinger Bands are 49.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 147.54 - 148.54 | 148.54 - 149.36 |
| Low: | 140.33 - 141.29 | 141.29 - 142.08 |
| Close: | 142 - 143.55 | 143.55 - 144.84 |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Tue, 15 Sep 2026
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup - ChartMill
Mon, 14 Sep 2026
California State Teachers Retirement System Raises Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Sun, 13 Sep 2026
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Fri, 11 Sep 2026
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Thu, 10 Sep 2026
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Tue, 08 Sep 2026
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 5.289e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 8,290 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 5.988e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 29.3 % |
| Operating Margin | 74.3 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | 10.9 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 418.54 |
| Sales Per Share | 1.57536e+008 |
| EBITDA (p.s.) | 1.57536e+008 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 131 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 19.72 |
| Dividend | 0 |
| Forward Dividend | 7.79e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|